CORPORATE PROGRAM

2015
SAN ANTONIO, TX
Grand Hyatt • May 6-9, 2015

AN EDUCATIONAL AND NETWORKING FORUM
FOR PROFESSIONALS IN THE FIELD OF APHERESIS MEDICINE
ADVANCING APHERESIS

Terumo BCT is committed to advancing therapeutic apheresis and cell collections. Through our collaboration with customers, we are enabling the best possible procedures today, increasing adoption of established uses, developing next-generation technologies and identifying new uses.

SEE HOW WE CAN ADVANCE APHERESIS TOGETHER:
VISIT TERUMOBCT.COM/ASFA
CORPORATE SUPPORTERS

ASFA wishes to acknowledge the support of all of the companies and organizations who contributed generously to the ASFA 2015 Annual Meeting.

KEYNOTE LEVEL SUPPORTER

TERUMO BCT
Unlocking the Potential of Blood

GOLD LEVEL SUPPORTER

Therakos
Advancing Immunotherapy

BRONZE LEVEL SUPPORTER

FRESENIUS KABI
caring for life

CONTRIBUTOR LEVEL SUPPORTERS

ALEXION  Baxter

SYMPOSIA SUPPORTERS

ALEXION  FRESENIUS KABI  octapharma  TERUMO BCT  Therakos

AWARD SUPPORTER

ITxM. The Institute for Transfusion Medicine®
WEDNESDAY, MAY 6, 2015

**CORPORATE DINNER SYMPOSIUM**

Supported by Octapharma

“Treatment Options for Thrombotic Thrombocytopenic Purpura US and European Experience with Octaplas™”

The focus of this session will be on sharing clinical experiences in managing Thrombotic Thrombocytopenic Purpura (TTP) patients in the United States and United Kingdom. A disease overview will be provided and advantages/disadvantages of different treatment options will be reviewed. Octaplas™, a solvent/detergent treated pooled plasma, is one of the treatment options that can be used for plasma replacement. More than 10 years of clinical experience with Octaplas™ from the UK and recent experience with this product from the US in treating TTP patients will be discussed.

Educational objectives:

- Thrombotic Thrombocytopenic Purpura (TTP): Overview of Disease and Diagnosis
- Treatment options for TTP
- Clinical experience from the US and UK in treating TTP patients with Octaplas™

Presented by: Karen E. King, MD, Associate Professor, Pathology and Oncology, Director, Hemapheresis and Transfusion Support, Associate Director, Transfusion Medicine, Johns Hopkins Hospital

Dr. King’s area of clinical expertise includes therapeutic apheresis and immunohematology.

Presented by: Marie Scully, MD, Consultant Haematologist, Department of Haematology, University College London Hospitals, London, United Kingdom

Dr. Scully’s area of clinical expertise includes hemostasis, thrombosis and blood transfusion.

THURSDAY, MAY 7, 2015

**BREAKFAST WITH THE EXPERT I**

Supported by Therakos

7:00am – 8:15am

Coffee Break

Supported by Fresenius Kabi USA, LLC

10:15am – 10:45am

Coffee Break

Supported by Fresenius Kabi USA, LLC

12:30pm – 1:30pm

**EXCLUSIVE CORPORATE LUNCH SYMPOSIUM**

Supported by Terumo BCT

“Transitioning Mononuclear Cell Collections from the COBE Spectra System to the Spectra Optia System”

Join us for this informative presentation on:

- Adopting new technologies and practices
- Process alterations and change management
- Mononuclear cell collection outcomes

Presented by: Eileen Schwartz, RN, BSN, Children’s Hospital Colorado

Attendees are eligible to receive continuing education credits.
**THURSDAY, MAY 7, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45pm – 4:15pm</td>
<td>Coffee Break</td>
<td>Supported by Fresenius Kabi USA, LLC Lone Star DEF &amp; Corridor</td>
</tr>
<tr>
<td>7:30pm – 9:30pm</td>
<td>CORPORATE DINNER SYMPOSIUM (by invitation only)</td>
<td>Supported by Therakos Bowie ABC</td>
</tr>
</tbody>
</table>

**FRIDAY, MAY 8, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am – 8:30am</td>
<td>BREAKFAST WITH THE EXPERT II Support by Therakos</td>
<td>Bowie ABC</td>
</tr>
<tr>
<td>12:30pm – 1:30pm</td>
<td>Concurrent Session CORPORATE LUNCH SYMPOSIUM Supported by Fresenius Kabi USA, LLC</td>
<td>Lone Star BC</td>
</tr>
<tr>
<td></td>
<td>“Implementation of a Therapeutic Apheresis Platform: A User’s Perspective”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fenwal Amicus MNC: A Blood Center’s Experience in Implementing a Platform for MNC Collection.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presented by: Lizette Caballero, BS, MT (ASCP), Senior Supervisor, Clinical Lab Scientist Specialist, UCSF Medical Center and Brenda Strzempkowski-Brun, RN, UCSF Medical Center</td>
<td></td>
</tr>
<tr>
<td>12:30pm – 1:30pm</td>
<td>Concurrent Session CORPORATE LUNCH SYMPOSIUM Supported by Alexion Pharmaceuticals</td>
<td>Lone Star A</td>
</tr>
<tr>
<td></td>
<td>“Understanding Atypical Hemolytic Uremic Syndrome (aHUS): Differential Diagnosis of TMAs”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss the importance of distinguishing aHUS from other thrombotic microangiopathies (TMAs) with similar clinical presentation</td>
<td>Lone Star A</td>
</tr>
<tr>
<td></td>
<td>• Understand aHUS is a chronic and life-threatening disease that arises from a genetic dysfunction of the complement system</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe laboratory and clinical considerations in the diagnosis of aHUS in patients who present with TMA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the diagnosis of aHUS in patients who present with complement amplifying conditions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify limitations of historical care options</td>
<td></td>
</tr>
</tbody>
</table>

**SATURDAY, MAY 9, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am – 8:30am</td>
<td>BREAKFAST WITH THE EXPERT III Supported by Therakos</td>
<td>Bowie ABC</td>
</tr>
</tbody>
</table>
EXHIBIT HOURS

Exhibits are located in Lone Star DEF and Corridor

- Wednesday, May 6, 2015 | 6:00pm – 8:00pm
- Thursday, May 7, 2015 | 10:00am – 8:00pm
- Friday, May 8, 2015 | 10:00am – 4:30pm

<table>
<thead>
<tr>
<th>Exhibitor List</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexion Pharmaceuticals</td>
<td>11</td>
</tr>
<tr>
<td>AngioDynamics Inc.</td>
<td>5</td>
</tr>
<tr>
<td>Asahi Kasei Medical America, Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Baxter Healthcare</td>
<td>6</td>
</tr>
<tr>
<td>Fresenius Kabi USA, LLC</td>
<td>1</td>
</tr>
<tr>
<td>Fresenius Medical Care/Apheresis Care Group</td>
<td>8</td>
</tr>
<tr>
<td>Healthcare-ID, Inc.</td>
<td>17</td>
</tr>
<tr>
<td>Kaneka Pharma America, LLC</td>
<td>10</td>
</tr>
<tr>
<td>Machaon Diagnostics</td>
<td>7</td>
</tr>
<tr>
<td>Norfolk Medical</td>
<td>15</td>
</tr>
<tr>
<td>Octapharma USA</td>
<td>9</td>
</tr>
<tr>
<td>Terumo BCT</td>
<td>2</td>
</tr>
<tr>
<td>Therakos</td>
<td>22</td>
</tr>
<tr>
<td>UC San Diego Health System</td>
<td>13</td>
</tr>
<tr>
<td>University of Virginia Therapeutic Apheresis Academy</td>
<td>14</td>
</tr>
</tbody>
</table>
Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in nearly 50 countries for the treatment of PNH and in nearly 40 countries for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris in additional severe and ultra-rare disorders beyond PNH and aHUS, and is developing other highly innovative biotechnology product candidates, including asfotase alfa, across multiple therapeutic areas. This press release and further information about Alexion can be found at www.alexion.com.

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Asahi’s Therapeutic Apheresis Division provides innovative therapies and medical devices for diseases with breakthrough technology for extracorporeal apheresis. In the dialysis market, Asahi Kasei Medical offers REXEED™ series dialyzers. REXEED™, the high performance polysulfone dialyzer, offers unparalleled performance and patient safety, and is offered in multiple sizes including 2.5 square meters.

Baxter’s renal care portfolio addresses the needs of patients and healthcare providers with a comprehensive range of therapeutic options across home, in-center and hospital settings. The portfolio includes innovative technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, multi-organ extracorporeal support therapy and additional dialysis services. Baxter scientists are also pursuing a range of next-generation monitors, dialyzers, devices and dialysis solutions.

Fresenius Kabi is a leading global health care company that focuses on pharmaceuticals and medical devices used to care for critically and chronically ill patients. Through our recent acquisition of Fenwal, we bring over 60 years experience in cell collection, separation and processing.
Today, the team is focused on serving the needs of the Therapeutic Apheresis and Cellular Therapy communities. The Gentle Science design of the Fenwal Amicus platform brings precision MNC collection and therapeutic plasma exchange (TPE) to customers. Recently launched, Lovo is the only cell processing system that washes and concentrates white blood cells using filtration technology.

**FRESENIUS MEDICAL CARE/APHERESIS CARE GROUP  BOOTH 8**

Fresenius Medical Care’s Therapeutic Apheresis Program provides high quality patient care, while substantially reducing the cost of these services to medical centers. We provide a fully equipped apheresis program to include state of the art equipment, specialty trained registered nurses and Medical Director oversight. We provide: Plasmapheresis, Leukocytapheresis, Thrombocytapheresis, Erythrocytapheresis, LDL Apheresis, Photopheresis. Treating: Thrombotic Thrombocytopenic Purpura (TTP), Sickle Cell Disease, Guillain-Barre Syndrom (GBS), Myasthenia Gravis, Autoimmune Polyneuropathies, Pulmonary Renal Syndrome, Systemic Lupus Erythematosus.

**KANEKA PHARMA AMERICA, LLC  BOOTH 10**

Kaneka Pharma America, LLC is dedicated to providing excellent service to our customers. Our Liposorber Lipid Apheresis treatment acutely lowers your patient’s LDL-C, LPA and triglycerides in one 2-3 treatment, with minimal effect on HDL-C or other essential plasma components.

**MACHAON DIAGNOSTICS  BOOTH 7**

Machaon Diagnostics is a clinical reference laboratory, specializing in the diagnosis, treatment and monitoring of hemostatic and thrombotic conditions. We serve as the STAT button for hospitals around the country providing 24-hour turnaround times for most of our testing menu. Our vision is to deliver customizable reference lab testing to the healthcare and bioscience industries.

**NORFOLK MEDICAL  BOOTH 15**

Norfolk Medical is a privately-held company that focuses on the design, manufacture, and distribution of medical devices. Since 1981, Norfolk Medical has provided innovative access solutions for the needs of healthcare providers and patients worldwide. All of our products are made domestically in our Skokie, IL facility, and we pride ourselves on producing the highest quality products on the market today.

Healthcare-ID's Donor-ID WebTM software automates documentation at fixed and mobile collection sites and interfaces to most BCDMS/BECS. Donor-ID WebTM modules include: Registration, Health History, Computer Assisted Self Interview (CASI), Internet CASI (iCASI), Physical Exam, Daily Quality Control at the Collection Site, Phlebotomy, Shipping, Donor Survey, Donor Adverse Reaction (developed for the AABB biovigilence project). Paperless operation is an available option.
OCTAPHARMA USA

Octapharma USA is a subsidiary of Octapharma AG, a global human protein products manufacturer. The company is dedicated to the research and manufacture of human proteins and has been committed to patient care and medical innovation for more than 30 years. Its core business is the development, production and sale of human proteins from human plasma and human cell-lines. Patients are treated with Octapharma products in the therapeutic areas of hematology, immunotherapy, and critical care. Octapharma USA is headquartered in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com, www.octagamus.net, www.octaplasus.com or www.wilateusa.com.

TERUMO BCT

A global leader in blood component, therapeutic apheresis and cellular technologies, Terumo BCT is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. Through our efforts in therapeutic apheresis and cell collections, Terumo BCT is committed to advancing apheresis. By collaborating with customers, Terumo BCT is enabling the best possible procedures today, increasing the number of clinicians adopting these procedures, identifying new uses and developing next-generation procedures. TERUMOBCT.COM

THERAKOS

Therakos is an immunotherapy company focused on providing innovative treatment platforms that harness the power of each individual patient’s immune system to fight disease. We are the global leader in autologous immune cell therapy delivered through extracorporeal photopheresis (ECP). Our therapeutic platforms, including the latest generation THERAKOS® CELLEX® Photopheresis System, are the world’s only approved, fully-integrated systems for administering autologous immune cell therapy through ECP. Our systems are used by academic medical centers, hospitals, and treatment centers in more than 30 countries and have already delivered over one million treatments globally.

UC SAN DIEGO HEALTH SYSTEM

UC San Diego Health System is San Diego’s only academic health system and is comprised of hospitals in San Diego, including UC San Diego Medical Center in Hillcrest, and UC San Diego Thornton Hospital, Moores Cancer Center, Shiley Eye Center, Sulpizio Cardiovascular Center and Jacobs Medical Center (opening in 2016) in La Jolla. UC San Diego Health System has one of the largest therapeutic
apheresis programs in the United States. Directed by David Ward, MD, an international leader in the field, the Apheresis Program is dedicated to the highest level of patient care. UC San Diego Health System Apheresis Program offers:

• The only photopheresis and LDL apheresis in San Diego County.
• Outpatient plasmapheresis, photopheresis, LDL apheresis, red cell exchange apheresis, white cell reduction apheresis, platelet reduction apheresis and hematopoietic stem cell harvest apheresis.
• The largest hematopoietic stem cell (HSC) collection facility in San Diego County.
• Onsite physician presence during treatment.
• Latest state-of-the-art technology.

UNIVERSITY OF VIRGINIA THERAPEUTIC APHERESIS ACADEMY

This conference focuses on advancing medical knowledge, expanding interpersonal and communication skills, and demonstrating the importance of therapeutic apheresis as part of a continuum of care. The educational formats include lectures and end of day wrap-ups with Q&A sessions. Speakers were chosen for their recognized expertise in their content area and for their practical experience in the daily operation of an apheresis service. The hands-on lab gives participants a chance to perform various tasks in a controlled setting.

Welcome to San Antonio

Malachite Management is proud to provide professional management services for the American Society for Apheresis since 2005.
For over 30 years, we have been focused on developing high-quality, life-saving products that support the health and well-being of patients around the world.

Please visit us at Booth #9 to learn more.

Get to know Octapharma better
Visit www.octapharma.com
SAVE THE DATE
NOVEMBER 20, 2015

REGIONAL MEETING
Puget Sound Blood Center Research Institute
SEATTLE, WASHINGTON

Contact us at asfa@apheresis.org for more information
Check the ASFA website at www.apheresis.org for any updates